Third-quarter sales rose 5.4% year over year as medication, monitoring and interventional businesses advanced, while Tom Polen said the first full quarter as New BD showed early benefits of a more focused MedTech company.
Becton, Dickinson and Co (NYSE:BDX) reported third-quarter adjusted earnings per share of $3.23, ahead of the $3.14 consensus, on sales of $4.983 billion versus the $4.887 billion Wall Street estimate. Sales increased 5.4% year over year, or 4.4% on a constant currency basis, as broad-based growth across medication, specimen, monitoring, biopharma and interventional businesses outweighed headwinds from volume-based procurement in China and lower vaccine-product demand. Tom Polen, chairman, CEO and president of BD, said the first full quarter as New BD showed early benefits of a more focused MedTech company, and the company raised full-year fiscal 2026 adjusted earnings per share guidance to $12.62-$12.72 from $12.52-$12.72, compared with a $12.61 consensus. BDX shares were up 3.91% at $177.33 at the time of publication on Thursday, according to Benzinga Pro data.